119th Congress · introduced in the House · Sep 10, 2025
RESULTS Act
Official title from Congress.gov
Latest action (Sep 10, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Sep 10, 2025)
Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 or the RESULTS Act
This bill requires the use of particular data from the private sector to inform Medicare payment rates for certain widely available laboratory tests.
Specifically, the Centers for Medicare & Medicaid Services (CMS) must contract with an entity that maintains a database of claims data for clinical diagnostic laboratory tests that (1) are not advanced diagnostic tests, and (2) were furnished by more than 100 providers and suppliers of such services over a specified six-month period (i.e., widely available tests).
The database must meet specified requirements, such as having data that is representative of the entire country and from more than 50 private payors and claims administrators. The contracted entity must be a nonprofit entity that is not affiliated with any government agency, any insurance issuer or provider, or any other organization in the health care sector.
Beginning January 1, 2028, the CMS must use the information obtained from the database to inform Medicare payment rates for these widely available laboratory tests.
The bill additionally specifies processes for determining payment rates for laboratory tests that are not advanced diagnostic tests, are not widely available, and lack adequate claims data. The CMS must use certain existing processes to set appropriate rates.
Show the full summary (1 more paragraphs)Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
195 citations; showing the 25 most recently posted.
QUEST DIAGNOSTICS INCORPORATED · lobbying firm or registrant: FEDERAL STREET STRATEGIES, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 21, 2026 · issue area: Medicare/Medicaid
$50,000
Paid to lobbying firm
Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R. 5269 - RESULTS Act S. 2761 - RESULTS Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CHRONIC CARE POLICY ALLIANCE · lobbying firm or registrant: CHRONIC CARE POLICY ALLIANCE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
Amount not reported
…ct H.R. 5256 - 340B ACCESS Act 340B Affording Care for Communities and Ensuring a Strong Safety-net Act SB 1973 - Treat and Reduce Obesity Act of 2025 SB 2761/ H.R. 5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. SB 932 - Give Kids a Chance Act of 2025 SB 339- Nancy Gardner Sewel…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
SUTTER HEALTH · lobbying firm or registrant: VENABLE LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
…mote monitoring; Home health / Hospice; Rural health and Rural Hospital Support Act (S. 335); Graduate medical education; Artificial intelligence; RESULTS Act (H.R. 5269 / S. 2761); Equitable Community Access to Pharmacist Services (ECAPS) Act (H.R. 3164 / S. 2426); 340B PATIENTS Act (H.R. 4581 / S. 2372); CONNECT for Health Ac…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SIEMENS MEDICAL SOLUTIONS USA, INC · lobbying firm or registrant: SIEMENS MEDICAL SOLUTIONS USA, INC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$510,000
Spent on own lobbying
…25 H.R. 6197 / S. 1399 - Health Tech Investment Act; H.R. 4417 / S. 2927 - Mobile Cancer Screening Act; H.R. 2120 / S. 1031 - ROCR Value Based Program Act; and H.R. 5269 / S. 2761 - RESULTS Act. Proposed Centers for Medicare & Medicaid Services Procedural Notice - Regulatory Alignment for Predictable and Immediate Device (RAPID…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
QUEST DIAGNOSTICS INCORPORATED · lobbying firm or registrant: QUEST DIAGNOSTICS INCORPORATED
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$300,000
Spent on own lobbying
S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act H.R. 6130…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
COMMISSION ON LABORATORY ACCREDITATION · lobbying firm or registrant: RUBRUM ADVISING
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
Amount not reported
H.R.5269 - RESULTS Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
AMERICAN HOSPITAL ASSOCIATION · lobbying firm or registrant: AMERICAN HOSPITAL ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$3,840,000
Spent on own lobbying
…tions for Medial Support (Rural MOMS) Act, all provisions; H.R. 3108 / S. 1535, Rural Patient Monitoring Access Act (RPM Access Act), all provisions; S. 2761 / H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act , all provisions; H.R. 5142, The Home Health Stabilization Act, a…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CAREDX, INC. · lobbying firm or registrant: TODD STRATEGY GROUP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
…jection. Medicare payment of clinical laboratory tests. Implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (H.R.5269). Prior authorization of molecular tests.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
QUEST DIAGNOSTICS INCORPORATED · lobbying firm or registrant: RED+BLUE STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
Policies, rules, and regulations related to clinical laboratories and Medicare coverage policies. H.R.5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare payments for lab tests. S.2761 - RESULT…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GENEDX, LLC · lobbying firm or registrant: RED+BLUE STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$80,000
Paid to lobbying firm
…eenings protocols for newborns and their families. Issues related to access and affordability for pediatric genetic tests for children and families nationwide. H.R. 5269 - RESULTS Act - issues related to Medicare payments for lab tests. S. 2761 - RESULTS Act - issues related to Medicare payments for lab tests.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MILLENNIUM HEALTH · lobbying firm or registrant: MANATT, PHELPS, AND PHILLIPS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$30,000
Paid to lobbying firm
Issues related to drugs of abuse testing; RESULTS Act (H.R.5269/S. 2761)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MILLENNIUM HEALTH · lobbying firm or registrant: MANATT, PHELPS, AND PHILLIPS
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$30,000
Paid to lobbying firm
Issues related to drugs of abuse testing; RESULTS Act (H.R.5269/S. 2761)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
LABORATORY CORPORATION OF AMERICA HOLDINGS · lobbying firm or registrant: KELLEY DRYE & WARREN LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$110,000
Paid to lobbying firm
Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement f…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ALZHEIMER'S ASSOCIATION · lobbying firm or registrant: ALZHEIMER'S ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$1,400,000
Spent on own lobbying
…ering Costs for Caregivers Act of 2025 (S. 1565 / H.R. 138) Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act (S. 2761 / H.R. 5269) Enhanced Alerts for Missing Loved Ones with Disabilities Act of 2026 (S. 4670 / H.R. 9118) Alzheimers Screening and Prevention Act (H.R. 6130/S. 3267) Other m…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
DH DIAGNOSTICS, LLC · lobbying firm or registrant: DH DIAGNOSTICS LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$310,000
Spent on own lobbying
Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ROCHE DIAGNOSTICS · lobbying firm or registrant: THE MCMANUS GROUP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$40,000
Paid to lobbying firm
H.R.5269/2761 - RESULTS Act Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transition…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY FOR HISTOCOMPATIBILITY AND IMMUNOGENETICS · lobbying firm or registrant: WHEAT SHROYER GOVERNMENT RELATIONS LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$20,000
Paid to lobbying firm
Issues surrounding laboratory reimbursement Issues surrounding CLIA Histocompatibility laboratory director requirements (S. 2761 / H.R. 5269) Reforming to Efficiently and Safely Utilize Laboratory Services Act (H.R.8890) Enhancing CLIA Act of 2026
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOMERIEUX, INC. · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$70,000
Paid to lobbying firm
…or development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOMERIEUX, INC. · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medical/Disease Research/Clinical Labs
$70,000
Paid to lobbying firm
…or development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Reforming technical certification of in vitro diagnostic…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
BIOMERIEUX, INC. · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$70,000
Paid to lobbying firm
…or development of new antibiotics. Reform of Medicare clinical laboratory payment per Section 216 of Protecting Access to Medicare Act, Pub. L. No. 113-93, and H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. Support for H.R.3164/S.2426, Ensuring Community Access to…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AEGIS SCIENCES CORPORATION · lobbying firm or registrant: MEHLMAN CONSULTING, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$30,000
Paid to lobbying firm
…erage and reimbursement for drugs, including accreditation issues. Clinical Laboratory Fee Schedule and Physician Fee Schedule Proposed Medicare Rules. S. 2761/H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 (The RESULTS Act).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CLINICAL LABORATORY ASSOCIATION · lobbying firm or registrant: ALSTON & BIRD LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$140,000
Paid to lobbying firm
Payment and regulation of clinical laboratory tests. H.R.5269/S.2761, The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN SOCIETY FOR MICROBIOLOGY · lobbying firm or registrant: AMERICAN SOCIETY FOR MICROBIOLOGY
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Health Issues
$50,000
Spent on own lobbying
Antimicrobial resistance; advanced molecular detection; national wastewater surveillance system (S.4048 - PREDICT Act); PAMA reform: RESULTS Act (H.R. 5269 S.2761); PASTEUR Act (H.R. 7352 and S. 4875); SUPER BUGS Act (H.R. 7879), and Stop Superbugs Act (S.5237).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medicare/Medicaid
$1,790,000
Spent on own lobbying
…tems and services furnished by certain essential community providers. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services. Access to Genetic Counselor Services Act, H.R.6280, S.3607. Bill would expand cover…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC · lobbying firm or registrant: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Medical/Disease Research/Clinical Labs
$1,790,000
Spent on own lobbying
…rom gross income certain compensation to clinical trial participants. Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, H.R. 5269, S. 2761. Bill would address Medicare reimbursement of laboratory services. Asal Sayas National Strategy on Young Adult Cancers Act, S. 4717: Directs the NIH t…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing